SABCS 2022 | The impact of adjuvant chemo on OS in HR+ and node+ BC with an Oncotype Dx score of 25 or less

Prashanth Ashok Kumar, MD, Upstate University Hospital, Syracuse, NY, talks on an investigation into the impact of adjuvant chemotherapy on overall-survival (OS) in hormone receptor positive (HR+), and node positive breast cancer. The Phase III RxPONDER (NCT01272037) trial showed that in premenopausal breast cancer (BC) subjects who were HR+, N1 lymph node status and had an OncotypeDx score of 25 or less, the use of adjuvant chemotherapy along with endocrine therapy had better disease-free and distant relapse-free survival than endocrine therapy alone. Using the 2004-2018 National Cancer Database (NCDB), the impact of adjuvant chemotherapy on OS in HR+ and node positive (N1, N2 and N3) breast cancer with an Oncotype Dx score of 25 or less was analyzed. In this retrospective analysis, adjuvant chemotherapy had a significant OS benefit. When dividing into subgroups of recurrent score of 0-11 and 12-25, only the 12-25 subgroup demonstrated a significant OS benefit. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.